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Purpose: In this study, the effect of the ethyl acetate fraction of the extract of Morinda morindoides 
(Baker) Milne-Redhead (Rubiaceae) on the tissue and metabolic integrity of rabbit liver was evaluated. 
Methods: Thirty rabbits (divided equally between male and female) were randomly distributed into five 
(5) groups of six (6) rabbits each. These animals received, by intraperitoneal injection, twice a week  the 
ethyl acetate fraction (F1) of the hydroalcohol extract of Morinda morindoides in doses ranging from 25 
to 100 µg/kg body weight for Groups 2 (Gp2) to 5 (Gp5) while Group 1 (Gp1) and control, received 1 ml 
of MacEwen physiological fluid. Blood sampling was carried out to evaluate various parameters: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-
glutamyltransferase (γGT), lactate dehydrogenase (LDH), total cholesterol, HDL cholesterol, 
triglycerides, glucose and total proteins  
Results: Analysis of the parameters following administration of the extract fraction showed slight 
increases in AST and ALT activities as well as the concentrations of total cholesterol and glucose, 
compared to their initial values. On the other hand, protein, glyceride, total cholesterol and high density 
lipoprotein cholesterol levels as well as the activities of ALP, γGT and the LDH did not change 
significantly (p >0.05). Nevertheless, the changes observed during the study were within the limits of the 
normal values for these various parameters in rabbit. 
Conclusion: These results revealed that the ethyl acetate fraction (F1) of the hydroalchol extract of 
Morinda morindoïdes, when used in the dose range evaluated in this study, may be well tolerated by the 
liver. 
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INTRODUCTION 
 
Morinda morindoïdes (Baker) Milne-Redhead 
(Rubiaceae) is well known in traditional 
medicine practice in some African countries 
(Nigeria, Democratic Republic of Congo and 
Congo-Brazzaville) where its leaves are 
frequently used for treating malaria, 
diarrhoea, amoebiasis, haemorrhoids, 
gonorrheoa and rheumatic pains [1-4]. In 
Ivory Coast, the leaf of the plant is 
traditionally used by people in the west 
central region against diarrhoea [4]. 
 
In vitro and in vivo studies on this plant have 
revealed some interesting results such as 
antimalarial [2], cardioinhibitory [5], 
antiamoebic [6], antifungal [7], antibacterial 
[3], antidiarrheal [4] and antispasmodic [8] 
activities. Phytochemical investigations on 
the plant led to the isolation of saponins, 
flavonoids, terpenes, steroids, tannins, 
anthraquinones and alkaloids [1,7] while 
structure elucidation indicated flavonoids 
[9,10], iridoids [6] and anthraquinones [11]. 
 
Studies have previously been performed to 
improve the antidiarrheoal activity of Morinda 
morindoides and isolate the compounds 
responsible of this activity. Among the 
different fractions tested, the ethyl acetate 
fraction (coded F1) of the hydroalcohol 
extract of M. morindoides offered the most 
promising biological activity [5,7]. 
 
Liver is a target organ and the primary site of 
detoxification. Being a major site of intense 
metabolism and, therefore, prone to various 
disorders as a consequence of exposure to 
toxins of extrinsic and intrinsic nature, the 
liver plays an important role in metabolism to 
maintain energy level and structural stability 
of the body [12]. It is also a site of 
biotransformation where toxic compounds are 
transformed to less harmful substances [12]. 
However, this function can result in damage 
to liver cells. 
 
To the best of our knowledge, in vivo 
tolerance studies on M. morindoides have not 
been extensively undertaken. This study was, 
therefore, conducted to assess the effect of  
the ethyl acetate fraction (coded F1) of the 
hydroalcohol extract of the plant on some 
biochemical markers of the liver since this 
fraction had previously been demonstrated to 




Plant material  
 
The leaves of Morinda morindoides (Baker) 
Milne-Redhead (Rubiaceae) were collected in 
the region of Daloa, west-central Ivory Coast. 
The plant was authenticated by Professor 
Ake Assi of the Department of Botany, 
University of Cocody, Abidjan and a voucher 
specimen (no. 17710) of the plant was 
deposited in the herbarium of the National 
Floristic Center of University of Cocody-
Abidjan. 
 
Preparation of Morinda morindoides 
extract 
 
The leaves of Morinda morindoides (Baker) 
Milne-Redhead (Rubiaceae) were air-dried at 
a room temperature (28 ±1 °C) for 7 days and 
ground into fine powder. The powder was 
mixed with distilled water (80 g in 2 L of 
distilled water) for 24 h with constant stirring 
at 80 °C. The extract was filtered twice 
through cotton wool, and then through 
Whatman filter paper no. 1. The filtrate was 
evaporated to dryness in a rotary evaporator 
(Buchi) at 60 °C. Twenty five grams of the dry 
aqueous extract was added to 500 ml of 
ethanol and water (consisting of 356 ml of 
ethanol 96 % and 144 ml of distilled water) 
and after thorough mixing, the supernatant 
was evaporated in a rotary evaporated 
following the method of Guede-Guina et al 
[13]. The residue was taken as the hydro-
alcohol extract. 
 
Preparation of the chromatographic 
fraction of the extract 
 
Five grams (5 g) of the hydro-alcohol extract 
was added to 500 ml of water/ethyl acetate 
mixture (consisting of 250 ml of distilled water 
and 250 ml of ethyl acetate) and stirred 
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continuously for 24 h. After decantation, the 
supernatant was evaporated in a rotary 
evaporator. The residue was taken as the 
ethyl acetate extract of the plant leaf (AcE). 
 
The ethyl acetate extract was subjected to 
separation on a chromatographic column (2 x 
50 cm) with silica gel 60 (Merck, silica gel, 
0.063 – 0.200 mm). The extract (0.25 g) was 
introduced into the column and placed on the 
silica gel, protected by cotton. 
Dichloromethane was used as eluent until 
total infiltration of the extract into the silica 
gel; thereafter, dichloromethane-methanol 
(95/5) mixture was used for elution until 
separation was complete. 
The four fractions obtained, based on their 
colour, were F1 (golden yellow), F2 (dark 
green), F3 (pale green) and F4 (yellow-
orange) [7]. Fraction F1 (AcE F1) was 
evaporated in a rotary evaporator (at 60 °C) 
before  use in the in vivo studies. 
 
Experimental animals  
 
Rabbits, Oryctolagus cuniculus, from a rabbit 
cattle farm in Bingerville, southern Ivory 
Coast were used in this study. The 
experimental procedures and protocols used 
in this study were approved by the Ethical 
Committee of Health Sciences, University of 
Cocody-Abidjan. These guidelines were in 
accordance with the European Council 
Legislation 87/607/EEC for the protection of 
experimental animals [14]. 
 
Administration of fraction F1 
 
Thirty (30) rabbits (15 males and females 
each) were acclimatized for a month and half 
at ambient temperature (28±1 °C) and 
humidity (70 ± 5%). Their age was approx. 3 
months and weighed 1.2 ± 0.2 kg on the 
average. They were randomly divided into 5 
groups of 6 rabbits each (3 males and 3 
females). Animals in each group were 
separated according to their sex in cages 
(length: 79 cm, width: 50 cm and height: 38 
cm). They had free access to both water and 
food. 
Twice a week, the animals received 
inraperitoneally (ip) 1 ml of an injection 
according to their group. Group 1 (Gp1), 
control, received 1ml of MacEwen 
physiological fluid while Groups 2 (Gp2) to 5 
(Gp5) were similarly injected with 30, 60, 60 
µg/ml , 90 and 120 µg/ml, respectively, of F1, 
equivalent to 25, 50, 75 and 100 µg/kg body 
weight, respectively 
 
Collection of blood  
 
Blood samples were obtained in the morning 
(from 8 to 11 am) via the marginal ear vein of 
the animals. Blood sampling was carried out 
once a week in the two weeks preceding the 
first application of treatment (S0), during the 
four weeks of treatment (S1, S2, S3 and S4), 
and then for two weeks after the treatment 
period (S5 and S6). These blood samples 
were collected in tubes (without 
anticoagulant) and centrifuged at 3000 rpm 
for 10 min. The serum was stored at -20 °C 
until analysed for enzymatic activities and 
concentration of biochemical metabolites. 
 
Assay of hepatic parameters in rabbit 
serum  
 
Hepatic parameters of the serum were 
measured with an automatic analyzer, Hitachi 
902 (Roche), using commercial kits and 
certified controls (Spinreact S.A., Ctra Santa 
Coloma, Spain) based on the manufacturer’s 
instructions, as summarized in Tables 1 and 2. 
 
Statistical analysis  
 
The results are presented as mean ± 
standard deviation (SD). Analysis of variance 
(ANOVA) with repeated measures was 
employed to compare the results according to 
the administered doses and times of 
treatment. Analysis of variance was 
considered significant when the level of 
probability (p) was < 0.05. When the value of 
p was significant, a Post-Hoc test of 
Newman-Keuls was carried out. These 
analyses were carried out with the software, 
Statistica 7.1 (Statistica, Statsoft) using a 
general linear model (GLM)  
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Table 1: Operating parameters for the quantitative 
determination of enzymes 
 
Parameter Enzyme kinetic method Wavelength  
(nm) 
ALT Disappearance of NADH 340 
AST Disappearance of NADH 340 
ALP Rate of p-nitrophenol  
formation 
405 
γGT Rate of NAMB 405 
LDH Disappearance of NADPH 340 
ALT= alanine aminotransferase; AST= aspartate 
aminotransferase; ALP=alkaline phosphatase; γGT= 
gamma-glutamyltransferase; LDH=lactate dehydrogenase; 
NAMB =2-nitro-5-aminobenzoic acid formation; 
NADH=nicotinamide adenine dinucleotide; 
NADPH=nicotinamide adenine dinucleotide phosphate 
 
Table 2: Operating parameters for the quantitative 
























Glucose Glucose oxydase 
and peroxidase 
500 






Effect of AcE F1 on hepatic enzyme  
activities of rabbit 
 
Table 3 shows the effect of F1 on liver 
enzyme activities. F1 increased the activity of 
AST compared to the control group (p = 
0.006) but the effect was not dependent on 
the concentration of the extract fraction. On 
the other hand, ALT (p = 0.15597), ALP (p  = 
0.52953), γGT (p  = 0.80844) and LDH (p  = 
0.0845) activities were not influenced by F1 
as they were statistically identical to those of 
the control group.  
 
Effect of AcE F1 on hepatic metabolites of 
rabbit 
 
Table 4 shows the effect of F1 on serum 
metabolites. With the exception of the 
concentration of total cholesterol which 
decreased compared to that of the control 
group (p = 0.02207), F1 had no significant 
effect on the levels of the other metabolites: 
HDL cholesterol (p = 0.15415), triglycerides 
(p = 0.67285), glucose (p = 0.10389) and 
total proteins (p = 0.65492). 
 
Effect of duration of AcE F1 
administration on hepatic enzyme 
activities of rabbit 
 
As Table 5 shows, the activities of the 
aminotransferases (AST and ALT) increased 
gradually after weekly administration of F1 
until the third week when maximum values of 
98.47 ± 6.57 (ALT, p = 0.000) and 88,27 ± 
4.42 (AST,  p = 0.000) were attained and no 
further changes were observed. For the other 
enzymes - ALP (p = 0.2257), γGT (p = 
0.0874) and LDH (p = 0.14310) - their initial 
activities were unchanged with time following 
weekly administration of the extract fraction.  




ALT (IU/L) AST (IU/L) ALP (IU/L) γGT (IU/L) LDH (IU/L) 
GP1 0 65.42 ± 5.28 67.55 ± 4.98
a
 76.55 ± 5.11 20.60 ± 2.59 106.87 ± 4.50 
GP2 25 63.83 ± 5.35 70.85 ± 4.37
b
 76.14 ± 4.71 19.95 ± 2.30 106.35 ± 4.19 
GP3 50 62.33 ± 3.69 71.99 ± 4.59
b
 74.22 ± 5.61 20.67 ± 2.10 108.67 ± 3.53 
GP4 75 58.67 ± 4.90 71.29 ± 4.24
b
 74.87 ± 5.38 20.52 ± 1.99 106.50 ± 4.31 
GP5 100 61.17 ± 5.19 70.54 ± 5.31
b
 76.87 ± 5.27 20.35 ± 1.85 107.03 ± 3.93 
Values are mean± SD (n = 6); values without common superscript (a or b)* in a column differ (p < 0.05); *a < b; ALT= alanine 
aminotransferase; AST= aspartate aminotransferase; ALP=alkaline phosphatase; γGT= gamma-glutamyltransferase; 
LDH=lactate dehydrogenase 
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Effect of duration of AcE F1 administration 
on hepatic metabolites of rabbit 
 
Table 6 indicates that the concentrations of 
total cholesterol (p = 0.0001) and glucose (p  
= 0.000) increased with weekly administration 
of F1 while the levels of cholesterol HDL (p = 
0.2615), triglycerides (p = 0.06311) and total 









T-C (g/L) HDL-C (g/L) Trig (g/L) Gluc (g/L) T-Prot (g/L) 
GP1 0 0.56 ± 0.05
b
 0.23 ± 0.04 0.76 ± 0.05 1.35 ± 0.06 58.31 ± 3.42 
GP2 25 0.53 ± 0.06
a
 0024 ± 0.04 0.74 ± 0.03 1.33 ± 0.04 57.48 ± 3.38 
GP3 50 0.53 ± 0.05
a
 0.23 ± 0.03 0.74 ± 0.04 1.33 ± 0.04 57.52 ± 3.53 
GP4 75 0.52 ± 0.04
a
 0.23 ± 0.03 0.76 ± 0.04 1.34 ± 0.07 57.69 ± 3.86 
GP5 100 0.52 ± 0.05
a
 0.23 ± 0.03 0.74 ± 0.05 1.35 ± 0.06 58.83 ± 2.59 
Values are mean ± SD (n = 6); values without common superscript (a-b)* in a column differ (p < 0.05); *a < b; T-C = Total 
cholesterol; HDL-C = HDL cholesterol; Trig = triglyceride; Glu = glucose; T-Prot = total protein 
 
 
Table 5: Hepatic enzyme activities of rabbit following weekly administration of M. morindoides ethyl acetate 
fraction (AcE F1) 
 
 
Week ALT (IU/L) AST (UI/L) ALP (IU/L) γGT (IU/L) LDH (IU/L) 
S0 54.96 ± 3.80
a
 60.33 ± 4.18
b
 75.23 ± 7.54 21.10 ± 1.93 106.99 ± 6.29 
S1 72.30 ± 5.40
d
 63.17 ± 5.78
b
 75.87 ± 7.30 20.93 ± 2.63 108.43 ± 4.13 
S2 95.73 ± 7.09
f
 86.70 ± 8.21
d
 74.90 ± 5.96 20.87 ± 2.79 107.60 ± 4.40 
S3 98.47 ± 6.57
g
 88.27 ± 4.42
d
 75.17 ± 5.52 20.20 ± 2.31 106.87 ± 3.85 
S4 88.47 ± 5.08
e
 81.67 ± 5.94
c
 74.63 ± 4.15 20.07 ± 1.91 107.57 ± 3.14 
S5 66.43 ± 5.33
c
 60.60 ± 4.90
b
 76.63 ± 4.11 19.83 ± 1.95 107.00 ± 4.15 
S6 58.1 ± 5.50
b
 52.37 ± 3.86
a
 77.67 ± 3.47 19.93 ± 2.23 105.13 ± 3.51 
Values are mean± SD (n = 6); values without common superscript (a - g) in a column differ (p < 0.05); *a < b < c < d < e 
< f < g ’ALT= alanine aminotransferase; AST= aspartate aminotransferase; ALP=alkaline phosphatase; γGT= gamma-
glutamyltransferase; LDH=lactate dehydrogenase S0 = two weeks preceding the first application of treatment; S1 to S4= 
weeks of treatment; S5 and S6= weeks after the treatment period  
 
Table 6: Hepatic metabolite levels (mean ± SD, n = 6) of rabbit following weekly administration of M. 
morindoides ethyl acetate fraction (AcE F1) 
 










S0 0.49 ± 0.08
a
 0.22 ± 0.03 0.75 ± 0.06 1.23 ± 0.04
a
 57.47 ± 3.50 
S1 0.54 ± 0.07
b
 0.24 ± 0.04 0.74 ± 0.05 1.29 ± 0.06
b
 58.57 ± 4.52 
S2 0.53 ± 0.06
b
 0.24 ± 0.04 0.74 ± 0.04 1.40 ± 0.08
b
 58.83 ± 3.03 
S3 0.56 ± 0.03
b
 0.23 ± 0.03 0.76 ± 0.05  1.38 ± 0.05
b
 58.73 ± 3.81 
S4 0.54 ± 0.05
b
 0.23 ± 0.04 0.76 ± 0.05 1.35 ± 0.06
b
 58.13 ± 3.30 
S5 0.53 ± 0.06
b
 0.22 ± 0.03 0.74 ± 0.04 1.36 ± 0.07
b
 57.17 ± 3.39 
S6 0.53 ± 0.05
b
 0.23 ± 0.04 0.75 ± 0.05 1.37 ± 0.06
b
 56.87 ± 4.70 
Values without common superscript (a-b)
  
in a column differ (p < 0, 05); *a < b;’ALT= alanine aminotransferase; AST= 
aspartate aminotransferase; ALP=alkaline phosphatase; γGT= gamma-glutamyltransferase; LDH=lactate ehydrogenase; 
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DISCUSSION  
 
Influence of ethyl acetate fraction on 
hepatic tissue integrity   
 
The levels of hepatic enzymes in many 
disease conditions in humans and other 
animals have been investigated extensively. 
Changes in these hepatic parameters have 
often proved to be an important aid in 
diagnosing select diseases and determining 
patients’ prognosis [15]. 
 
Increase in the activities of ALT, AST, ALP, γ-
GT and LDH in plasma is mainly due to the 
leakage of theses enzymes from the liver 
cytosol into the blood stream, an occurrence 
that reflects liver damage and disruption of 
normal liver function [15]. The initial levels of 
the various enzymes (ALT, AST, ALP, γ-GT 
and LDH) found for the control group are in 
conformity with the respective normal values 
reported by Medirabbit [16] and Founzegue 
et al [17]. The findings of the present study 
indicate that although aminotransferase 
levels increased during the first 3 weeks of 
treatment they returned to their initial values 
subsequently with further treatment. This 
result is better than that obtained for fraction 
F5 in a previous work where the 
aminotransferase levels remained high 
throughout the treatment period [18]. 
According to the interpretation of Schmidt 
and Schmidt [15], the initial increase in the 
enzyme levels found in the present study is 
moderate and transient and would not cause 
irreversible damage to the liver. Moreover, 
the increases observed were within the limits 
of the standard values of aminotransferases 
in rabbits [16]. Therefore, fraction F1, if used 
within the dose range of 25 to 100 µg/kg body 
weight would not have harmed hepatic cells. 
 
 Effect of AcE F1 on hepatic metabolism   
 
The values of the hepatic metabolites (total 
cholesterol, cholesterol HDL, triglycerides, 
glucose and total proteins) obtained in this 
study prior to commencement of F1 treatment 
are in agreement with those stated by 
Medirabbit [16] and Founzegue et al [17]. 
According to Xavier [19], liver plays a role in 
the metabolism and regulation of glucose, 
lipids and proteins and any damage to the 
liver would lead to an increase in the levels of 
these metabolites. However, the present 
study reveals that only the concentration of 
total cholesterol and glucose showed a 
slightly increase; the concentrations of the 
other metabolites did not change. The slight 
increase in total cholesterol and glucose 
levels may be due to the lipid in food [20] and 
the effect of Morinda morindoides on insulin 
activity or on the metabolism of glycogen [20] 
rather than damage to hepatic cells. Notably, 
even these slight changes in these levels 
were neither  dose- nor time-dependent and 
furthermore, they were within the limits of 
their standard values in rabbit, thus 
suggesting that fraction F1, when used in the 
tested dose range, would not be detrimental 




The changes in hepatic aminotransferases 
and hepatic metabolism following 
administration of the ethyl acetate fraction of 
the hydroalchol extract of Morinda 
morindoides are small and transient. Overall, 
this fraction did not appear to exert any 
noxious effect on hepatic tissue or 
metabolism and should thus be well tolerated 
by the liver. It would, however, be necessary 
to carry out further studies, including 
cardiovascular, and renal tolerance studies 
as well as hematological and 
histopathological investigations in order to 
obtain a fuller picture of the safety profile of 
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